Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.

European journal of medical research

Volumn 4, Issue 3, 1999, Pages 101-104

  Kurowski, M ^a   Muller M ^a   Donath, F ^a   Mrozikiewicz, M ^a   Mocklinghoff C ^a  

^a Vivantes Auguste Viktoria Klinikum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; METABOLIC CLEARANCE RATE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HALF-LIFE; HIV; HIV PROTEASE INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; RITONAVIR; SAQUINAVIR;

EID: 0033605488     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)